Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE)

BACKGROUND: Initial trials of lung-targeted budesonide (0.25 mg/kg) in surfactant to prevent bronchopulmonary dysplasia (BPD) in premature infants have shown benefit; however, the optimal safe dose is unknown. METHODS: Dose-escalation study of budesonide (0.025, 0.05, 0.10 mg/kg) in calfactatant in...

Descripción completa

Detalles Bibliográficos
Autores principales: McEvoy, Cindy T., Ballard, Philip L., Ward, Robert M., Rower, Joseph E., Wadhawan, Rajan, Hudak, Mark L., Weitkamp, Joern-Hendrik, Harris, Julia, Asselin, Jeanette, Chapin, Cheryl, Ballard, Roberta A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223897/
https://www.ncbi.nlm.nih.gov/pubmed/32006953
http://dx.doi.org/10.1038/s41390-020-0792-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223897/
https://www.ncbi.nlm.nih.gov/pubmed/32006953
http://dx.doi.org/10.1038/s41390-020-0792-y

Ejemplares similares